newsfilter
← Latest News
GlobeNewswire·

Scopus BioPharma Announces FDA Approval of IND Application for Lead Drug Candidate

CpG-STAT3siRNA is a Distinctive RNA Therapy and Immunotherapy Developed at City of Hope A Phase 1 Clinical Trial Will be Initiated at City of Hope NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced t